Brintellix differs from traditional SSRIs or SSNRIs chemically and functionally. Therefore, dosing guidelines also differ. Increasing the dosage of Brintellix provides MDD patients with additional benefits other medications do not offer. During this episode, we discuss the data, collected from research and clinical trials, that support increasing the dosage of Brintellix from 10 mg to 20 mg for most MDD patients, considerations for patients with comorbidity, and what side effects, if any, patients may experience when taking Brintellix.
Dr. Fagiolini is a Professor of Psychiatry at the University of Siena School of Medicine, Siena, Italy. He currently serves as Chairman, Chief of Medical Services, and Residency Training Director of the Department of Mental Health and Division of Psychiatry.
Key Takeaways:
[:49] For MDD patients, discovering the optimal dose of Brintellix means achieving optimal results.
[2:18] Recommendations for increasing the dosage of Brintellix based on Professor Fagiolini's professional experience.
[5:53] Published research and clinical trials that support increasing dosage of Brintellix from 10 mg to 20 mg for an MDD patient.
[12:04] Professor Fagiolini explains how increasing a dose of Brintellix differs from SSRIs and SSNRIs.
[17:46] The dose-dependent efficacy of Brintellix in elderly patients.
[19:33] Professor Fagiolini's recommendations for dosing Brintellix in patients who have comorbidity.
Resources:
